Technology Development for Polarizer and Detector Instrumentation

偏振器和探测器仪器的技术开发

基本信息

批准号：
10611458
负责人：
Daniel B Vigneron
金额：
$ 31.76万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-08-01 至 2027-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10611458
关键词：
2,4-Dinitrophenol Abdomen Advisory Committees Animal Model Animals Attention Automobile Driving Brain Brain Diseases Clinical Clinical Research Communities Data Development Documentation Educational workshop Engineering Environment Extramural Activities Feedback Funding Future Guidelines Heart Diseases Human Industry Industry Collaboration Institution International Leadership Liquid substance Liver diseases Magnetic Resonance Imaging Malignant Neoplasms Methods Patients Performance Pharmacists Pharmacy facility RF coil Reporting Research Personnel Resources S10 grant SP1 gene Sampling Site Speed Sterility System Technology Test Result Testing Tissues Training Training Activity Translations United States National Institutes of Health Vendor Visualization clinical translation cost design detector ergonomics human data human subject improved in vivo innovation instrument instrumentation interest manufacture manufacturing facility metabolic imaging molecular imaging new technology next generation novel patient oriented perfusion imaging pre-clinical preclinical study radiologist rapid technique reconstruction skills technology development technology research and development transmission process web site

项目摘要

TRD1 Project Summary/Abstract This Technology Research & Development (TRD) project in the Hyperpolarized MRI Technology Resource Center (HMTRC) is responsible for developing, maintaining and improving the “beyond state-of-the-art” polarizer and MRI hardware technologies required for all hyperpolarized (HP) 13C MRI studies performed & supported by this P41 Center’s TRDs, CPs and SPs. Since its inception in 2011, this TRD has been highly successful in developing and disseminating novel technologies for preclinical HP MRI worldwide, and driving first-ever HP 13C studies in humans. As stated in the recent External Advisory Committee’s 2021 report: “Since the last competitive renewal, the number of sites that have begun acquiring data from human subjects has risen from one – UCSF – to twelve, all of which have been supported by the HMTRC. Of the 36 trials that are registered on ClinicalTrials.gov, the majority (21) are now being carried out at other institutions that have benefitted from the outstanding leadership of the HMTRC… The HMTRC has led the nation (and the world) in the development and translation of HP MRI through a unique combination of skills, expertise, instrumentation, environment, clinical engagement, and industry engagement, which simply does not exist elsewhere”. In this renewal project, new dissolution DNP technology will be developed by TRD1 to achieve higher polarizations for HP probes (TRD2), driven by the needs of all CPs with iterative push-pull optimization & specialized training. TRD1 technology resources will be disseminated and used by SPs and the international HP 13C scientific community with feedback on performance, quality of training, and ease of dissemination. TRD1 will develop improved polarization, dissolution and sample delivery technologies required for all CPs, SPs and TRDs. New DNP and MR hardware for preclinical studies will be driven by the needs of CPs together with TRD2. Clinical innovation will be driven by CP1,3-6,8-10,13. The HP pharmacy team will create robust, reduced-cost, sterile HP 13C-probe manufacturing methods that meet FDA guidelines. TRD1 will develop novel 13C RF exciters and detectors, working closely with TRD3 to create and test new methods for data reconstruction, visualization and analysis. These methods will be developed in a push-pull fashion, driven by the CPs for metabolic imaging of liver disease (CP2,6), cardiac disease (CP2), cancer (CP1,3,4,8,9,13), brain disorders (CP5,10) and HP perfusion imaging (CP7). A major focus of this TRD1 project will also be the specialized training of new intra- & extramural investigators both through hands-on training at this P41 center and via webconferences, on-line website documentation, training modules and videos.

TRD1 项目摘要/摘要超极化 MRI 技术资源中的该技术研发 (TRD) 项目中心（HMTRC）负责开发、维护和改进“超越最先进”的偏光片以及所有超极化 (HP) 13C MRI 研究所需的 MRI 硬件技术该 P41 中心的 TRD、CP 和 SP 自 2011 年成立以来，该 TRD 在以下方面取得了巨大成功。在全球范围内开发和传播临床前 HP MRI 新技术，并推动首个 HP 13C 正如外部咨询委员会最近发布的 2021 年报告中所述：“自上次竞争以来更新后，开始从人类受试者获取数据的站点数量已从 1 个增加 – UCSF – 已注册的 36 项试验中，共有 12 项试验得到了 HMTRC 的支持。 ClinicalTrials.gov 上显示，大多数（21 项）目前正在其他受益于该计划的机构进行 HMTRC 的杰出领导...... HMTRC 领导了国家（和世界）的发展和通过技能、专业知识、仪器、环境、临床的独特组合来转化 HP MRI 参与度和行业参与度，这在其他地方根本不存在。” 在本次更新项目中，TRD1将开发新的溶解DNP技术，以实现更高的 HP 探头 (TRD2) 的极化，由所有 CP 的需求驱动，具有迭代推挽优化和 TRD1 技术资源将由 SP 和国际 HP 传播和使用。 13C 科学界将提供有关绩效、培训质量和传播便利性的反馈。开发所有 CP、SP 和 TRD 所需的改进的偏振、溶解和样品传输技术。用于临床前研究的新 DNP 和 MR 硬件将由 CP 和 TRD2 的需求驱动。创新将由 CP1,3-6,8-10,13 推动，惠普药房团队将创造强大的、低成本的无菌产品。符合 FDA TRD1 指南的 HP 13C 探针制造方法将开发新型 13C 射频激励器和。探测器，与 TRD3 密切合作，创建和测试数据重建、可视化和这些方法将以推拉方式开发，由用于代谢成像的 CP 驱动。肝病 (CP2,6)、心脏病 (CP2)、癌症 (CP1、3、4、8、9、13)、脑部疾病 (CP5,10) 和 HP 灌注成像 (CP7) 该 TRD1 项目的一个主要重点也将是新的内部和外部的专门培训。校外调查人员通过 P41 中心的实践培训和网络会议、在线网站文档、培训模块和视频。